Autism affects about 2% of children in the United States, and about 30% of these children have seizures. A new study has pointed towards the molecular cause of some of these seizures and potential treatments.

A team has figured out why protein production slows down in the nerve cells of people suffering from Charcot-Marie-Tooth disease. This discovery could lead to a new therapeutic approach.

Ground-breaking new research has discovered a possible new pathway that may kickstart Alzheimer’s disease, in a significant finding that offers potential new prevention and treatment opportunities.

New research has found elevated cholesterol supply from astrocytes to neurons in the model of Alzheimer's disease (AD) brains, suggesting that modulating brain cholesterol could be explored in the search of treatment options for the devastating, degenerative disease.

In baseball, batters have roughly 50 milliseconds to decide whether to swing. Despite this short window, batters still manage to hit the ball roughly 25 percent of the time. The mechanisms underlying these feats are at the center of new research.

In a study published this month in Communications Biology, researchers from Tokyo Medical and Dental University (TMDU) have revealed that the protein HMGB1 is a key player in both frontotemporal lobar degeneration and Alzheimer disease, two of the most common causes of dementia.

The hypothesis that raising the brain levels of the natural antioxidant urate could slow the progression of Parkinson’s disease (PD) has been disproven by researchers at Massachusetts General Hospital (MGH).

Glioblastoma's dependency on biotin distribution suggests that biotin-dependent metabolism and epigenetic pathways could be targeted therapeutically to treat the disease.

In June 2021, the Food & Drug Administration (FDA) granted accelerated approval for aducanumab to treat patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease. A new study has shown that the vast majority of Medicare enrollees with these diagnoses would have excluded been excluded from the aducanumab clinical trials, raising questions about side effects of the drug in vulnerable populations.

Northwestern Medicine scientists have developed an antibody that they believe can be used to treat muscular dystrophy, findings that were published in Science Translational Medicine.